Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Trial ID or NCT#

NCT04340141

Status

recruiting iconRECRUITING

Purpose

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Official Title

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

George A. Poultsides, MD, MS
George A. Poultsides, MD, MS
Hepatobiliary surgeon, Pancreatic surgeon, Liver surgeon, Sarcoma specialist, Gastrointestinal specialist, Minimally invasive surgeon
Professor of Surgery (General Surgery) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

Contact

gitrialeligibility@stanford.edu